Drug Trial Radar · NCT04711850
An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR
Last checked: Nov 19, 2026Latest source record: May 28, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
18
Actual
Start
Jan 20, 2021
Primary completion
Mar 30, 2023
Study completion Mar 30, 2023
Sponsor
- Lead sponsor
- Hansa Biopharma ABIndustry
- Sponsor type
- Industry
- First posted
- Jan 15, 2021
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aim of this trial is to collect data and provide a better understanding of the long-term outcome of imlifidase treatment on active or chronic active antibody-mediated rejection (AMR) in kidney transplant recipients. This is done by collecting data during an extended follow-up period of 3 years of clinical study trial 16-HMedIdeS-12, in which patients received either imlifidase or plasma exchange (PE) as AMR treatment. Data for parameters such as kidney graft survival, patient survival, kidney function, treatment of rebound of donor specific antibodies (DSA) and anti-drug antibodies (ADAs) are collected.
Conditions
- Kidney Transplant Rejection
Interventions
ImlifidaseDrug
Immunoglobulin G degrading enzyme of Streptococcus pyogenes
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Graft Survival at Year 3Time frame: 3 years after start of AMR treatment in feeder study (16-HMedIdeS-12)
Locations
7 sites in 3 countries. Site status is shown where the registry gives one.
Universitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie MUW
Vienna, Austria
Hôpital Pellegrin
Bordeaux, France
CHU Grenoble Alpes - Néphrologie, dialyse et transplantation
Grenoble, France
Hôpital Saint-Louis. Service de Néphrologie et Transplantation
Paris, France
Hôpital Necker - Service de Néphrologie - Transplantation
Paris, France
Charité-Universitätsmedizin. Dept. of Nephrology and Medical Intensive Care
Berlin, Germany
Medizinische Hochschule Hannover
Hanover, Germany
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.